Our latest articles
A renewed push into early bladder cancer
Ferring's Adstiladrin has joined Keytruda with a US approval, but it might not be the answer doctors are looking for.
Novartis trims its pipeline
Discontinuations for branaplam, iptacopan and Piqray could increase pipeline scepticism, but more pruning is coming.
Astrazeneca gets personal
A collaboration this week with the blood testing specialist Capitainer underlines the big pharma’s ambition to have a diagnostic linked with every pipeline project.
Go or no go? Overcoming delays
US Pdufa decisions loom for Apellis and Travere, while Menarini and Lilly got their approval firsts already.
The end of the Humira era
With $219bn in accumulated sales the Abbvie mega-blockbuster is biopharma’s best-selling drug. Can Keytruda do better?
Anthos doubles down on its novel blood thinner
The group continues its niche-targeting strategy with abelacimab’s latest pivotal trial.
Xylocor sees enough to press on with angina gene therapy
A pivotal trial is in the works, but can the group succeed where other VEGF gene therapies have failed?
Immuno-oncology goes subcutaneous
A pivotal study of Keytruda’s SC formulation is about to read out, but Roche could get to market first.
Medtech investments hold up despite market turmoil
Medtech venture funding started strongly in 2022, but a slump in the fourth quarter could give rise to concern.
A year to forget for medtech stocks
The biggest surprise is that there were a handful of risers despite the widespread market turmoil.
